Kirby McInerney LLP Reminds DexCom, Inc. Investors of Important Deadline in Class Action Lawsuit

If you have suffered a loss on your DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ:DCXM) investment, contact Thomas W. Elrod of Kirby McInerney LLP by email at [e-mail], or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost.

Investors have until December 26, 2025 to ask the Court to appoint them as lead plaintiff.

[CONTACT THE FIRM IF YOU SUFFERED A LOSS]

What Is The Lawsuit About?

The lawsuit has been filed on behalf of investors who purchased securities during the period of July 26, 2024 through September 17, 2025, inclusive (“the Class Period”). The lawsuit alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (i) DexCom had made material design changes to the G6 and G7 unauthorized by the FDA; (ii) the foregoing design changes rendered the G6 and G7 less reliable than their prior iterations, presenting a material health risk to users relying on those devices for accurate glucose readings; (iii) accordingly, Defendants’ purported enhancements to the G7, as well as the device’s reliability, accuracy, and functionality, were overstated; (iv) Defendants downplayed the true scope and severity of the issues and health risks posed by adulterated G7 devices; and (v) all the foregoing subjected DexCom to an increased risk of heightened regulatory scrutiny and enforcement action, as well as significant legal, reputational, and financial harm.

On March 7, 2025, DexCom disclosed in a filing with the U.S. Securities and Exchange Commission (“SEC”), that, three days earlier, it had received a warning letter from the U.S. Food and Drug Administration (“FDA”) related to concerns about manufacturing processes and quality management systems at certain of the Company’s facilities. On this news, the price of DexCom shares declined by $7.12 per share, or approximately 9.15%, from $77.84 per share on March 7, 2025 to close at $70.72 on March 10, 2025.

On March 25, 2025, the FDA published the Warning Letter on its website, revealing that DexCom had “adulterated” its G6 and G7 glucose monitors by “modifying the G6 and G7 sensors” without prior regulatory approval, thereby subjecting the devices to “larger inaccuracies” that “cause higher risks for users who rely on the sensors to dose insulin or make other diabetes treatment decisions.” On this news, the price of DexCom shares declined by $1.77 per share, or approximately 2.4%, from $75.32 per share on March 24, 2025 to close at $73.55 on March 25, 2025.